Chardan Capital Markets initiated coverage on Silence Therapeutics with a new price target

3/31/22 8:57:01 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Chardan Capital Markets initiated coverage of Silence Therapeutics with a rating of Buy and set a new price target of $33.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SLN

Date	Price Target	Rating	Analyst
2/11/2025	$6.00	Sell	Goldman
12/2/2024		Outperform	BMO Capital Markets
9/3/2024	$40.00	Buy	Jefferies
1/31/2024	$67.00	Outperform	BMO Capital Markets
5/8/2023	$20.00	Overweight	Morgan Stanley
12/9/2022	$18.00	Equal-Weight	Morgan Stanley
3/31/2022	$33.00	Buy	Chardan Capital Markets